TP53 H193R

CI-VAR-00001915Explore in graph →NP_000537.3:p.His193ArgNM_000546.5:c.578A>GClinVar 184979 CIViC 1079 rs786201838

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
TP53 H193R	MDM2 Inhibitor AMGMDS3	Predictive	D	Supports Resistance	3	submitted	EID10063 Subset of 58 cancer cell lines with unaltered TP53 is sensitive to MDM2 Inhibitor AMGMDS3. None of 115 cancer cell lines with TP53 mutation and absence of WT allele are sensitive to MDM2 Inhibitor. TP… (full text at CIViC) PMID 25730903 · Saiki et al., 2015 · Open in CIViC	civic
Sarcoma1
TP53 R175H OR TP53 H193R	Pazopanib + VorinostatCombination	Predictive	C	Supports Sensitivity Response	2	accepted	EID7540 In the phase I study of pazopanib and vorinostat in 36 patients with advanced solid tumors, detection of hotspot TP53 mutation was associated with a higher rate of SD ≥6 months/PR, longer median PFS (…

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
184979	Pathogenic/Likely pathogenic	criteria provided, multiple submitters, no conflicts	2	Hereditary cancer-predisposing syndrome; Squamous cell carcinoma of the head and neck; Li-Fraumeni syndrome; Ovarian neoplasm; Li-Fraumeni syndrome 1; Adrenocortical carcinoma, hereditary; Diffuse midline glioma, H3 K27M-mutant	germline/somatic	11	May 29, 2026